CNS Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
CNS Therapeutics, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include GABLOFEN. The owner is based in St. Paul, MN.
Suite W1750
332 Minnesota Street
St. Paul, MN 55101
Showing of trademarks Trademarks
Trademark Classifications
CNS Therapeutics, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does CNS Therapeutics, Inc. have?
CNS Therapeutics, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 2 cancelled.
What trademark classes does CNS Therapeutics, Inc. file in?
CNS Therapeutics, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are CNS Therapeutics, Inc.'s most well-known trademarks?
CNS Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as GABLOFEN. These are among 1 currently registered trademark in the portfolio.
What is CNS Therapeutics, Inc.'s trademark registration success rate?
CNS Therapeutics, Inc. has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.